Alternative splicing of the primary glucocorticoid receptor (GR) transcript, resulting in glucocorticoid receptor alpha GRa, glucocorticoid receptor beta GRb and glucocorticoid receptor gamma GRc, may influence glucocorticoid (GC) resistance in childhood leukemia. To test this hypothesis, we determined GRa/b protein and GRa/b/c mRNA expression levels in 43 initial acute lymphoblastic leukemia (iALL), 10 initial myeloid leukemia (iAML), 11 relapsed ALL (rALL) samples and one rAML sample. The results were correlated with in vitro GC resistance. GRa mRNA correlated with protein expression (q ¼ 0.39-0.56, Po0.05), but the protein to mRNA ratio was median 2.2-fold lower in rALL than in iALL (Po0.05). GRb mRNA was median 137-fold lower than GRa mRNA and correlated with GRa mRNA expression (q ¼ 0.71, Po0.0001). GRb could not be detected at the protein level. GRc accounted for a median of 2.8% (range 0.95-7.4%) of all GR transcripts. GRa (protein and mRNA) and GRb (mRNA) expressions or GRa/GRb ratios did not correlate with in vitro GC resistance in iALL, but GRc (mRNA) did (q ¼ 0.52, P ¼ 0.007). These results suggest that GRb is not involved in GC resistance in childhood leukemia. The association between GRc expression and in vitro GC resistance in iALL and the decreased protein/mRNA ratio in rALL, a subgroup resistant to GCs, warrants further exploration.
Introduction
Glucocorticoids (GCs) are the cornerstone in the treatment of childhood leukemia. Especially, the initial acute lymphoblastic leukemias (iALL) are uniquely sensitive to the lytic actions of GCs. [1] [2] [3] [4] [5] However, in a significant proportion of these patients GC resistance is present or develops, which has an adverse effect on cure rates. In addition, acute myeloid leukemia (AML) and relapsed ALL (rALL) patients are highly resistant to GCinduced cell kill. 6, 7 The cell lytic effect of GCs is mediated through the glucocorticoid receptor (GR). The amino-acid sequence of the GR was first described by Hollenberg et al 8 in 1985 . They identified two human GR isoforms termed GC receptor alpha (GRa) and beta (GRb). The analysis of the protein structure revealed that both receptor isoforms share the same amino-acid sequence up to amino acid 727, but diverge from this position with GRa having an additional 50 amino acids and GRb an additional nonhomologous 15 amino acids. Exons 1-8 of the GR gene contain the 5 0 noncoding and coding sequences common to the GRa and GRb. Alternative splicing of the large exon 9 generates the mRNA coding for the GRa and GRb.
The GRa has been the primary focus of subsequent research, due to its predominant expression, ligand-binding properties and transcriptional activity. GRb does not bind GCs and is transcriptionally inactive. 8 The GRa is a 97 Kd a protein that is organized into structurally and functionally defined domains: the highly variable region that includes a transactivation domain that is required for the regulation of gene expression, the DNA-binding domain crucial for the specific interaction between the receptor and the GC-responsive elements and the carboxyl-terminus involved in hormone binding, interaction with heat-shock proteins (hsp's), nuclear translocation, receptor dimerization and transactivation. [9] [10] [11] [12] [13] [14] [15] [16] [17] In the absence of hormone, the GRa predominantly resides in the cytoplasm as a multiprotein complex consisting of the GR itself, two molecules of hsp90 and several other proteins. [18] [19] [20] Upon binding of a GC, the receptor complex dissociates and translocates to the nucleus. In the nucleus, the GR binds as a homodimer to GC-responsive elements, which are usually found in the promotor regions of GC-responsive genes. 21, 22 The receptor then communicates with the basal transcription machinery resulting in enhancement or repression of gene transcription. 23 In addition, the receptor modulates gene transcription by physically interacting with other transcription factors like AP-1 and NF-kB. 24, 25 Many studies have been published describing the relation between clinical response and GRa expression in childhood lymphoblastic leukemia, but receptor expression levels appeared to be of limited clinical usefulness. [26] [27] [28] [29] These observations have led many researchers to believe that clinical resistance to GCs should be sought further downstream in the GC lytic pathway.
During the past decade, the GRb has been increasingly studied. Oakley et al 30 demonstrated that GRb, despite the fact that it is transcriptionally inactive, influences GC-mediated gene transcription. They showed that the GRb was capable of binding and inactivating GRa, thus inhibiting signal transduction. However, this was not always confirmed. 31 Most clinical evidence that GRb is capable of decreasing GC sensitivity of target cells has been obtained in respiratory medicine. Various authors showed that GRb expression in airway cells and peripheral blood mononuclear cells obtained from patients with GC-resistant asthma was higher than in patients with GC-sensitive asthma or normal s ubjects. 32, 33 So far, only one study has been published investigating GRa and GRb levels in pediatric leukemia samples. 34 Longui and co-workers found significantly lower GRa/GRb ratios in T-ALL (a subgroup relatively resistant to GCs) than in common/pre-B ALL. However, the number of patients studied was small (nine controls, 13 ALL patients). In addition, correlations with in vivo or in vitro treatment response were not studied.
More recently, a third splice variant of the GR was identified: the GRg. 35 Owing to the use of an alternative splice donor site, three base pairs are retained between exons 3 and 4. As a consequence, an mRNA sequence is produced coding for an additional amino-acid (arginine) located in the region between the two zinc-fingers of the DNA-binding domain. Although steroid receptors show considerable conservation of amino-acid sequences in their DNA-binding domain, consistent with the functional importance of this region, amino-acid insertions at the same site in the GR have been described. Ray and coworkers described a small-cell carcinoma cell line that expressed a GR with a similar arginine insertion into the DNA-binding domain, although they assumed it to be the result of a mutation. 35 Interestingly, they suggested that the GCresistant phenotype of this cell line might be explained by this amino-acid insertion as transfection studies demonstrated a strong reduction in the transcriptional activity of this receptor. The clinical significance of GRg expression, however, is unknown.
The goal of the present study was to investigate the correlation between GRa/GRb/GRg expression and in vitro GC resistance in childhood leukemia. This way, we tried to find out whether alternative splicing of the GR contributes to the differential GCresistance profiles observed in childhood leukemia.
Materials and methods

Patient samples
Bone marrow or peripheral blood samples taken for routine diagnostic procedures were obtained from 43 iALL, 10 iAML, 11 (unpaired) rALL and one rAML patient with informed consent. Mononuclear samples were separated by sucrose densitygradient centrifugation (Ficoll Paque, density 1.077 g/ml; Pharmacia, Sweden). The percentage of leukemic cells was determined morphologically by May-Grü nwald-Giemsa (Merck, Germany) staining of cytospin preparations. When necessary, the percentage of malignant cells was enriched to 480%, using monoclonal antibodies linked to magnetic beads (Dynabeads, Norway) to eliminate contaminating cells. 36 Immunophenotype was defined as precursor B-lineage (HLA-
were included in this study.
RNA extraction and reverse transcriptase reaction
Total RNA of 5 Â 10 6 cells was isolated using RNAzol (Campro Scientific, Veenendaal, The Netherlands) according to the manufacturer's protocol, with minor modifications: the chloroform-phenol extraction step was repeated and the precipitation step in isopropanol at À201C was extended to overnight.
Next, total RNA was reverse transcribed by M-MLV-RT (Murine Leukemia Virus Reverse Transcriptase; Promega, Madison, WI, USA), including RNase inhibitor (0.6 IU/ml), bovine serum albumin (0.2mg/ml), dNTPs (1 mM) and random hexamers (45 ng/ml) in 50 ml at 421C for 2 h. After incubation, the mixture was heated to 951C to denature M-MLV-RT and stored at -201C.
Preparation of competitive templates standard mixtures
Primers to synthesize competitive templates (CTs) (F and R1R2) and for the amplification of the native target (NT) (F and R1) were selected by Oligo software as described previously. 37, 38 The selection of the primers was based on an optimal annealing temperature of 581C, the absence of hairpins and no tendency for primer-dimer formation. Selected primers are summarized in Table 1 .
CTs were synthesized by the amplification of a cDNA sample obtained from a CEM cell line, which expressed both GRa and GRb mRNA. In this PCR reaction, similar forward primers were used as for the amplification of the NT, but different (hybrid) reverse primers (R1R2). These hybrid primers consist of the reverse primers used for the amplification of the NT (R1) and a primer situated more upstream (R2). The thus obtained PCR products, approximately 75% the length of the NT, were pooled, separated on an agarose gel, gel purified and quantitated by coelectrophoresis with a size marker, as described previously. 37, 38 Coamplification using primer F and R1 of a cDNA sample with known amounts of the CTs will result in two PCR products of different lengths, which can be separated by gel electrophoresis and quantified by densitometry after ethidium bromide staining.
CTs were mixed in combinations that were based on pilot experiments using 10 patients samples. For this study, several stocks were prepared containing a mixture of CTs for b-actin, GRa and GRb in fixed ratios: (a) 10 À10 /10
, and (c) 10
. These mixtures could subsequently be diluted further without disturbing the initial relationships of the CTs present.
Competitive template polymerase chain reaction
In order to normalize the expression of the target genes to the expression of b-actin and in order to allow accurate determinations of GRa/GRb ratios, one single master mix was prepared for every cDNA sample containing PCR buffer (1 Â ), MgCl 2 , dNTPs (200 mM), sample cDNA and the appropriate CT mix in a total volume of 41 ml. Primers (4 ml, final concentration 4 ng/ml) specific for the different targets (b-actin, GRa, GRb) were added to separate aliquots of this master mixture. Reaction mixtures were overlaid with mineral oil (Sigma, St Louis, MO, USA) and cycled in an MJ Research PTC-200 (Biozym, Landgraaf, The Netherlands) with 1 min steps of denaturation at 941C, primer annealing at 581C and elongation at 721C for 35 cycles. The first Table 1 Primers used for the construction of CTs and for coamplification of the NT and the corresponding template. cycle included a 7 min denaturation step, whereas in the last cycle, the elongation period was extended to 7 min. In case of the GRb amplification, the PCR was preceded by 17 annealings/ elongation cycles during which the annealing temperature was decreased stepwise from 701C with 0.51C/cycle (touch down protocol) in order to improve sensitivity and specificity. PCR products were separated by 130 V electrophoresis for 3 h on 2% agarose gels containing 0.1 mg/ml ethidium bromide. The results were analyzed by densitometry. Concentrations of NT molecules can be calculated using the NT/CT ratio and the molarity of the CT mixture. Pixel intensity (PI) staining has to be corrected for fragment size, as the intensity of PI staining is linearly related to the number of base pairs (bp). In addition, heterodimers (HD) consisting of the NT and CT molecules were taken into account ( Table 2 ). The results were evaluable when the ratio NT/CT was between 0.1 and 10 for GRa and b-actin and between 0.1 and 6 for GRb. All PCRs were performed in triplicate. The mean variation between triplicate experiments was 26% (713%) for GRa normalized to b-actin and 35% (718%) for GRb normalized to b-actin.
Quantitation of GRg mRNA
The cDNA region spanning the exon 3/exon 4 boundary were: 5 0 -GGA GAT CTG GTT TTG TCA AG-3 0 (sense) and 5 0 -GAA GAC ATT TTC GAT AGC GG-3 0 (antisense). The conditions used for PCR were: 35 cycles of 941C 15 s, 541C for 39 s, 721C for 40 s. PCR products were purified and digested with ACC I prior to analysis during 1 h at 371C. In case the three base pair insertion is present, an ACC I restriction site is created (GTkAGAC) and consequently the 670 bp product is cleaved into 573 and 97 bp products. Next, PCR products were separated by 100 V electrophoresis for 3 h on 2% agarose gels containing 0.1 mg/ml ethidium bromide. In all the samples tested, the 573 and 670 bp products could be visualized. The 97 bp product could only be visualized after increasing the amount of amplified cDNA loaded on gel (PI staining is linearly related to the number of bp and signal intensity was thus low). The results were analyzed by densitometry. The expression of GRg was expressed as a percentage of the total GR message as follows: %GRg¼ððPI 570bp fragment=lengthÞ =ððPI 570bp fragment=lengthÞ þðPI 670bp fragment=lengthÞÞÂ100%
All experiments were performed in triplicate. The mean variation between triplicate experiments was 28% (714%).
GRa and GRb protein detection
Cell lysates for GRa detection were prepared as follows: a 1 ml cell suspension of 2-10 Â 10 6 cells/ml was washed three times in PBS. After the third wash, the pellet was resuspended and lysed in 80 ml lysis buffer/1 Â 10 6 cells (5 M NaCl, 0.5 M Tris-HCl, 0.4% sodium dodecyl sulfate (SDS), 1% Triton-X, one tablet Completet (Boehringer Mannheim, protease inhibitor cocktail tablets: 1697498)/50 ml lysis buffer) during 1 h at 41C. Lysates were clarified by microcentrifugation at 14 000 g during 10 min. Next, Laemli's sample buffer (Biorad 161-073) supplemented with 50 ml of b-mercaptoethanol/1 ml was added (lysis: Laemli ¼ 2:1) and lysates were boiled for 3 min.
Cell lysates for GRb were prepared as follows: a washed pellet of 10 Â 10 6 cells was lysed in 100 ml lysis buffer as described above. After clearing the lysate of cellular debris by centrifugation at 14 000 g for 10 min, lysates were diluted with 900 ml RIPA buffer (1xPBS, 0.1% SDS, 1% Igepal CA-630 (Sigma Chemicals), 0.5% sodium deoxycholate and one tablet of Completet (Boehringer Mannheim, protease inhibitor cocktail tablets: 1697498)/50 ml lysis buffer. Next, 0.6 mg of anti-GRa/b (SantaCruz; SC-1003) was added and incubated for 1 h at 41C. Next, 20 ml of resuspended agarose conjugate (Protein A-Agarose, Santa-Cruz: SC-2001) was added and incubated at 41C overnight. Immunoprecipitates were collected by centrifugation at 1000 g for 5 min at 41C. The pellet was washed 4x in RIPA buffer and after the final wash the pellet was resuspended in 20 ml lysis buffer þ 10 ml Laemli's sample buffer and boiled for 3 min.
Cell lysates (20 ml: the equivalent of 2.5 Â 10 5 cells for wholecell lysates or 7 Â 10 6 cells for immunoprecipitates) were separated by SDS-polyacrylamide gel electrophoresis (PAGE) (7.5-12.5%) and electroblotted (30 V, 12 h) onto nitrocellulose membranes (Biorad: 162-0115). Next membranes were washed 1 Â during 15 min in PBS, incubated for 1 h in blocking buffer (0.1% Tween-20, 5% nonfat dry milk blocking grade (Biorad) in PBS). Blots were incubated with commercially available antibodies against the GRa (rabbit polyclonal, Santa-Cruz: SC-1002), GRb (Affinity Bioreagents, PA3-514) and b-actin (mouse monoclonal (clone c4), Boehringer Mannheim) for 1 h at room temperature in 1% blocking buffer (0.1% Tween-20, 1% nonfat dry milk (Biorad: 170-6404) in PBS). After four washes in PBS-T (0.1% Tween-20 in PBS), membranes were incubated with goat anti-rabbit-HRP (Santa-Cruz: SC-2004) or goat anti-mouse-HRP (DAKO: p0447) during 1 h. After four washes in PBS-T, peroxidase activity was visualized using an ECL kit (Amersham pharmacia biotech: RPN 2106). GRa signal intensity was determined densitometrically and expressed as compared to the internal standard (an ALL patient sample included in all experiments whose values were arbitrarily set at 1). b-actin was used for normalization. All experiments were performed in duplicate. The mean variation between duplicate experiments was 24% (712%). GRb protein could only be visualized in the positive control, an immunoprecipitate of 10 Â 10 6 CEM-C7 cells. H-DXM binding was determined using the whole-cell assay as described by Costlow et al 39 with minor modifications. 40 . Briefly, cell suspensions of 1-4 Â 10 6 /ml were incubated with a receptor saturating concentration (50 nM) of 3 Ci/mol) in the presence (low specific activity) and absence (high specific activity) of a 500-fold excess of nonradioactive DXM during 45 min at room temperature in duplicate. Next, the cell suspensions were centrifuged and radioactive media were replaced by steroid-free media in order to reduce nonspecific binding. After 10 min incubation, the cell suspensions were Table 2 Quantitation of mRNA expression Variant
Ligand binding (LB) assay
The cells were washed three times in ice-cold PBS containing 1% fetal calf serum. Before the last centrifugation step, a small sample was taken for cell counting. Cell number and volume were determined using an electronic cell counter (Casy s 1 cellcounter, Schärfe Systems). Cells were then lysed in 0.1 N NaOH and the amount of radioactivity was determined by scintillation counting. Specific 3 H-DXM binding was calculated as described previously. 40 By including the cell volume in the equation, the intracellular receptor concentration could be calculated (nM). The mean variation between duplicate experiments was 10% (74.5%).
Methyl-thiazol-tetrazolium salt assay
The assay conditions were essentially the same as described previously. 36, 41 Briefly, aliquots of 80 ml cell suspension (1À2 Â 10 6 cells/ml) were added to 96-well microculture plates containing 20 ml aliquots of drug solutions. Leukemic cells were exposed to six concentrations of prednisolone (PRD) in duplicate for 4 days. Control leukemic cells were cultured in the absence of drugs. After 4 days of culturing, we added 10 ml of 5 mg/ml MTT (Sigma) to each well. The microculture plates were shaken gently for 1 min and incubated for 6 h. The yellow tetrazolium salt MTT is reduced to dark-colored formazan by viable cells only. Formazan crystals were dissolved in 100 ml acidified isopropanol. The optical density (OD) was measured at 565 nM with an EL-312 microplate reader (Biotek Instruments Inc., USA). The OD is linearly related to the number of viable cells. 41 After correction for the OD of the culture medium, leukemic cell survival (LCS) was calculated as follows:
LCS ¼ ðOD drugÀexposed well Þ=ðmean OD control wells ÞÂ100%
Only samples with more than 70% blasts at day 4 in the control wells and with a control OD higher than 0.050 U (adjusted for blank values), both required for reliable test results, 36 were used to calculate the LC 50 value, that is, the PRD concentration lethal to 50% of the blasts. Patients were classified as sensitive (LC 50 PRD p0.1 mg/ml), intermediately resistant (LC 50 PRDo150mg/ ml, but 40.1 mg/ml) or resistant (LC 50 PRD X150 mg/ml) to GCinduced cell kill. This classification has been shown to correlate with clinical response in childhood Iall.
2,3
Statistics
The correlation between two variables was tested by the Spearman's rank-correlation test. The Mann-Whitney U-test was used for the analysis of unpaired observations, the Wilcoxon's signed-rank test for paired observations. A P-value p0.05 was considered to be statistically significant (two-tailed analysis).
Results
Validation of CT-RT-PCR
Coamplification of the CT and NT (ie GRa/b) showed that both fragments were amplified with equal efficiency; the ratio NT/CT was similar before and after amplification. The slopes obtained by plotting the ratio of CT/NT initially present (varying from 0.1 to 10 for GRa and from 0.1 to 6 for GRb) vs the ratio obtained after amplification was 1.1 for GRa and 1.0 for GRb. The mean fit coefficients (r 2 ) for GRa and GRb were, respectively, 0.98 and 0.97. Sequence analysis confirmed that the amplified fragments belonged to GRa and GRb.
GRa mRNA expression vs protein expression
GRa expression was determined at the mRNA level competitive template reverse transcriptase polymorase chain reaction (CT-RT-PCR) and at the protein level (Western blotting (WB) and (LB) assay). Receptor expression determined by WB and LB correlated strongly with each other. This was observed in each leukemia subgroup separately: iALL r ¼ 0.77, Po0.0001, n ¼ 35; rALL r ¼ 0.85, P ¼ 0.004, n ¼ 9; iAML r ¼ 0.94, P ¼ 0.005, n ¼ 6), and also after combining all leukemia samples (including one rAML sample; r ¼ 0.73, Po0.0001, n ¼ 51).
GRa mRNA expression correlated with protein expression determined by LB (r ¼ 0.50, P ¼ 0.0001, n ¼ 56; Figure 1) , and by WB (r ¼ 0.39, P ¼ 0.003, n ¼ 54) in the study population as a whole. In each subgroup separately, only in iALL samples a statistically significant correlation between mRNA and protein expression was found: r ¼ 0.56, P ¼ 0.0005, n ¼ 38 when determined by LB, r ¼ 0.39, P ¼ 0.02, n ¼ 35 when determined by WB. The group of rALL and iAML patients, however, was small.
GRa/b/g expression in childhood leukemia
The results of GRa/b/g expression in the different leukemia subtypes are summarized in Table 3 . GRb mRNA was median 137x lower than GRa mRNA (range 26-1805; n ¼ 63) and correlated with GRa expression (Figure 2) . At the protein level, GRb could be visualized in an immunoprecipitate of CEM-C7, but not in any of the patient samples (Figure 3) . The 3 bp insertion typical for GRg occurred in median 2.8% of all GR mRNA (range 0.95-7.4%; n ¼ 47).
Figure 1
Correlation between GRa mRNA and protein expression as determined by LB assay. The former was normalized with b-actin mRNA. The latter was expressed in nanomolars (nanomol GRa/l cell volume).
Variant receptor expression in childhood leukemia EG Haarman et al
Within iALL samples, T-ALL (n ¼ 11) expressed significantly (Po0.05) lower GRa levels than common/pre-B samples (n ¼ 26) both at the mRNA (median 1.7 Â 10 À3 vs 9.5 Â 10
À3
GRa mRNA/b-actin mRNA (P ¼ 0.01)) and protein level (median 0.46 vs 1.3 arbitrary units determined by WB (P ¼ 0.004) and median 28 vs 66 nM (Po0.001) determined by LB). Also, GRb mRNA levels were significantly lower in T-ALL than in common/ pre-B ALL: median 1.2 Â 10 À5 vs 4.5 Â 10 À5 GRb mRNA/b-actin mRNA (Po0.05). GRa/GRb ratios did not differ significantly: 154 vs 166 (P ¼ 0.48). The percentage of GRg did not differ between T-ALL (n ¼ 17) and common/pre-B ALL (n ¼ 8): median 2.8 vs 2.4% (P ¼ 0.44). Two pro-B and four iALL samples with unknown immunophenotype were excluded from these analyses.
GRa mRNA levels (expressed as compared to mRNA levels of b-actin) were 3.8-fold higher in rALL than in iALL samples (P ¼ 0.006). At the protein level, rALL and iALL samples expressed similar levels of GRa, both when determined by WB and LB (Table 3) . Consequently, rALL samples had a significantly lower protein/mRNA ratio than iALL samples (median 3608 vs 7624 nM/mRNA GRa (normalized to b-actin) when protein was determined by LB, or median 80 vs 185 GRa protein (arbitrary units)/ mRNA GRa (normalized to b-actin) when protein was determined by WB (Po0.05). rALL samples expressed 3.5-fold higher GRb mRNA levels than iALL samples (Po0.01). GRa/GRb ratios were similar in rALL and iALL (median 207 vs 154; P ¼ 0.80). GRg levels did not differ significantly between iALL and rALL (2.6 vs 2.8%, P ¼ 0.70).
AML samples expressed over two-fold lower levels of GRa mRNA than the other leukemia subgroups (Po0.05). GRa protein expression determined by LB was two-fold lower in iAML than in iALL samples (P ¼ 0.03), which is in line with their lower mRNA expression levels. A similar difference was found for GRa protein expression determined by WB (median 0.72 versus 1.1 arbitrary units), but this difference did not reach statistical significance (P ¼ 0.28). GRb levels were similar in iALL and iAML (0.037 vs 0.032 GRb mRNA/b-actin mRNA). iAML showed a significantly lower GRa/GRb mRNA ratio (median 87) than the other leukemia subgroups (Po0.05). GRg expression was similar in iALL and iAML (2.6 vs 3.0%, P ¼ 0.83).
Variant receptor expression vs GC resistance in iALL
GRa expression did not correlate with GC resistance, neither when determined at the mRNA (r ¼ 0.11; P ¼ 0.50) nor protein level (r ¼ 0.06 (WB) and À0.05 (LB), respectively; P40.05). GRb mRNA expression was not associated with GC resistance (r ¼ À0.07, P ¼ 0.66). There was no relationship between in vitro GC resistance and GRa/b ratios (r ¼ 0.22, P ¼ 0.20). GRa/b ratios did not differ significantly between sensitive, Table 3 GRa/b/g expression in the different leukemia subtypes Correlation between GRa and GRb mRNA expression in 63 leukemia patients as determined by CT-RT-PCR. GRa and GRb mRNA levels are expressed as compared to b-actin mRNA levels.
Figure 3
Western blot analysis of GRb expression in childhood ALL (lane [3] [4] [5] [6] and AML samples (lane 7-10). As a positive control an immunoprecipitate of CEM-C7 was used (lanes 1 and 2) . GRb was not detectable in any of the patient samples. The light (b) and heavy (a) chains of SC-1003 (anti-GRa/b IgG) are also visualized.
Variant receptor expression in childhood leukemia
EG Haarman et al intermediately resistant and resistant patients (median sensitive 121, intermediately resistant 195 and resistant 226, P40.05; Figure 4 ). GRg mRNA expression correlated with GC resistance (r ¼ 0.52, P ¼ 0.007, n ¼ 26). Resistant and intermediately resistant patients expressed significantly higher levels than sensitive iALL patients (median 4.2 and 2.7% vs 2.0%, Po0.05; Figure 5 ).
Meaningful correlations between GRa/b/g and GC resistance could not be established in iAML and rALL because of the relatively small number of patients (n ¼ 10 and 11, respectively) and the high incidence of highly resistant patients (median LC 50 PRD in AML 4250 mg/ml, in rALL 31 mg/ml vs iALL 0.37 mg/ml).
Discussion
The cause of GC resistance in childhood leukemia is largely unknown. The GR has been directly linked to GC resistance.
Altered expression levels, genetic alterations (polymorphisms), alternative splicing (GRa/b/g/P) and secondary modifications of this protein (eg mono-ADP ribosylation) have been suggested to influence cell sensitivity to GC treatment. 35, [41] [42] [43] [44] [45] [46] In this study, we focused on the expression levels of the GR splice variants GRa, GRb, and GRg in relation to in vitro GC resistance in childhood leukemia.
GRa expressions (at both the protein and mRNA level) were highly variable in all leukemia subgroups, with levels being lower in T-ALL and iAML samples, confirming the results previously obtained by our group 40 and others. 26, 39, 47 We did not find an association between GRa expression and in vitro GC resistance in iALL, which contrasts with the data previously reported by our group. 40 This difference may be explained by the fact that the number of GC-resistant patients classified as T-ALL, a subgroup with comparatively low GR levels, differs; in the latter study, approximately 6/10 resistant iALL samples were T-ALL, whereas in this study only 3/11 resistant samples were classified as such.
GRa mRNA expression correlated with protein expression. However, in rALL we observed a decreased protein to mRNA ratio, suggesting that a less efficient translation of mRNA into protein occurs, or that protein is more rapidly degraded. This phenomenon may be of importance as various studies have shown that for GC-induced cell lysis, autoinduction of the GR is required. 48, 49 This upregulation may be hampered by a less efficient mRNA translation or increased protein degradation. Consequently, the GR/GC-mediated signal may not be sufficient to induce apoptosis. However, it still remains to be established whether upregulation of GR expression is required for GCinduced apoptosis in rALL. The fact that decreased protein to mRNA ratios were observed in rALL, a leukemia subgroup over 75-fold more resistant to GC-induced cell lysis, 6, 7 suggests a possible link between this process and the acquisition of GC resistance. This is the first study quantitating GRa/GRb mRNA levels using a CT-PCR. In the leukemia samples tested, we found a median 85-to 200-fold lower GRb mRNA than GRa mRNA expression, which is slightly higher than the results previously reported by Oakley et al 30 (0.22% in CEM) and Honda et al 50 (0.16% in normal lymphocytes). We were not able to detect GRb at the protein level. This may be caused by low (or absent) levels of the GRb protein. As we did not include a known amount of purified GRb in the experiment, we cannot exclude the possibility that failure to detect the GRb is the result of a comparatively low affinity of the GRb antisera used. However, based on the low mRNA levels it seems likely that protein levels are also low or absent. Transfection studies have demonstrated that a GRb to GRa ratio of 10:1 is required for significant inhibition of GRa function. 43 The relatively low GRb mRNA levels that were found in this study (median 85-to 200-fold lower than GRa) indicate that it is unlikely that the GRb is capable of inhibiting GRa-mediated cell lysis in childhood leukemia. In accordance with this, we were not able to demonstrate a significant correlation between GRb mRNA expression or GRa/GRb mRNA ratios and in vitro GC resistance.
The 3-bp insertion typical for GRg was found in approximately 3% of the total GR message, which is in line with the results previously published by Rivers et al. 35 Of particular interest is the fact that GRg mRNA expression correlated with in vitro GC resistance in iALL. Given the multifactorial nature of GC resistance and the heterogeneity of clinically obtained specimens, this correlation (r ¼ 0.52) is relatively strong. In line with our data, preliminary results obtained by Gerdes and Figure 4 GRa/GRb mRNA ratios in GC-sensitive (LC 50 PRD p0.1 mg/ml) intermediately resistant (LC 50 PRD40.1 but o 150 mg/ ml) and resistant patients (LC 50 PRD X150 mg/ml). Median ratios are depicted as horizontal lines (sensitive 121, intermediately resistant 195 and resistant 226, P40.05).
Figure 5
GRg mRNA expression in sensitive (LC 50 PRD p0.1 mg/ ml) intermediately resistant (LC 50 PRD40.1 but o150 mg/ml) and resistant patients (LC50 PRD X150 mg/ml). Resistant and intermediately resistant patients expressed significantly higher levels than sensitive iALL patients (median 4.2 and 2.7% vs 2.0%, Po 0.05).
Variant receptor expression in childhood leukemia EG Haarman et al co-workers demonstrated a possible link between GRg expression and a poor in vivo response to PRD monotherapy in pediatric iALL (Gerdes et al. Quantification of the glucocorticoid receptor and its splice variant gamma in childhood acute lymphoblastic leukemia was carried out using real-time PCR. Blood 2001; 98: 113a; abstract). Based on what is known about the GRg so far, it is difficult to explain the relation between GRg expression and GC resistance in iALL. Ray et al 51 showed that a 3-bp insertion at the same location in the GR of a carcinoma cell line resulted in an approximately 50% reduction of transcriptional activity. 51 In addition, Kasai et al 52 previously reported a GR with (also) an arginine inserted at the same site resulting in a similar reduction in transcriptional activity. It seems unlikely that a 50% reduction in transcriptional activity in up to 7.4% of the GR proteins (assuming that the mRNA transcript is as efficiently translated as GRa) results in a GCresistant phenotype.
Several alternative hypotheses can be proposed. First GRg overexpression may be related to GC resistance due to confounding bias; that is, the expression of the GRg may be related to other (unkown) factors that induce GC resistance in pediatric iALL. This factor may for example favor directly or indirectly the use of the alternative splice donor site between exons 3 and 4, but induce GC resistance through different pathways. Second, apart from reduced transactivating activity, the arginine insertion in the DNA-binding domain may influence, which GC-responsive genes are transcribed. Different cell types within one organism respond differently to GC exposure varying from induction to inhibition of apoptosis, or even induction of cell proliferation. [53] [54] [55] [56] Very little is known about the mechanisms that determine which GC-responsive genes are transactivated or transrepressed upon the activation of the GR. It does not seem unlikely that structural changes in the DNA-binding domain influence this process. The effect of an activated GRg on cellular apoptosis may thus differ from (or even oppose) GRa. Future studies are warranted to clarify these aspects of GRg function.
In conclusion, the low expression levels of GRb mRNA and the lack of association with in vitro GC resistance challenge the concept that the GRb acts as a significant inhibitor of GRa activity in childhood leukemia. The association between GRg expression and in vitro GC resistance in iALL warrants further investigation. The fact that decreased protein to mRNA ratios were observed in rALL, a leukemia subgroup over 75-fold more resistant to GC-induced cell lysis, suggests a possible link between this process and the acquisition of GC resistance.
